Phase 2 Study of 153 Sm-EDTMP [samarium 153-SM lexidronam] Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2015
At a glance
- Drugs Samarium 153 lexidronam (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Sep 2010 Planned end date changed from 1 Mar 2010 to 1 Mar 2017 as reported by ClinicalTrials.gov.